Indication intelligence, analysis and sector perception

Asterias Biotherapeutics, Inc. (NYSE MKT: AST) new CFO

November 2, 2015 7:44am

Georgia Erbez was appointed to the position of Chief Financial Officer of NYSEMKT: AST effective 11/9/15.

Ms. Erbez joins Asterias after serving as a financial consultant to numerous biotechnology companies and previously serving as Chief Financial Officer, Secretary, and Treasurer of Raptor Pharmaceutical Corp. She will report to Asterias's President & CEO Pedro Lichtinger and will be based at the Company's Menlo Park, California headquarters.

Ms. Erbez served as Raptor's CFO, Secretary, and Treasurer from 2012 to 2014. She was a key member of the management team that guided Raptor through a growth phase including first drug approval and commercial drug launch. Prior to Raptor, Ms. Erbez was a Managing Director, Healthcare Investment Banking at Collins Stewart, a senior level investment banker at Beal Advisors, Jeffries & Company, Inc. and Cowen and Company. She has also held positions of increasing responsibility at the investment banks Hambrecht & Quist and Alex, Brown & Sons Inc. Ms. Erbez was awarded a Bachelor of Arts degree, International Relations from the University of California at Davis.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

3 hours 23 min ago
RegMed Investors (RMi) Closing Bell: start thinking of sector equities’ future direction without the geopolitical cloud overhead

14 hours 24 min ago
RegMed Investors’ (RMi) pre-open: Start BUYING-in after a 5-session downhill slide

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.